ANZCTR search results

This research aims to identify modifiable hospital, GP and family factors associated with asthma re-admissions in children. The findings from this research will be used to inform practical interventions and solutions to reduce child asthma re-admissions to hospitals.

This study is evaluating the effect of the PICCsox arm cover on peripherally inserted central catheter (PICC) dislodgments in patients receiving a PICC Who is it for? You may be eligible to join this study if you are aged 18 years or above, and are booked for PICC insertion in the Radiology Department of the Royal Adelaide Hospital. You may or may not be diagnosed with cancer. Study details Participants will be randomised by chance (like flipping a coin) into two groups: one group will receive a PICCsox arm cover to wear over their PICC for six weeks. The other group will not receive anything to wear over their PICC for the intervention period but will be offered a PICCsox after the six week intervention period, if they still have a PICC in place. Participants will be telephoned and asked about whether their PICC came out early and their experiences and views of the PICCsox. Participants will be selected based on their diagnosis (haematological cancers, solid tumours, infection and those who required a PICC due to difficult venous access) as we hope to get wide range of patients. This study will help Nurses and doctors know whether they should give patients a PICCsox when they have a PICC inserted to stop it coming out and to help with daily life.

Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of aggressive Non-Hodgkin Lymphoma (NHL), accounting for 30-40% of all NHL cases. To assess the risk for DLBCL, doctors use tools like the International Prognostic Index (IPI), aaIPI, and NCCN-IPI. These tools help identify high-risk patients but are not good at spotting those at "ultra-high-risk" (UHR) of treatment failure within two years of diagnosis. The NHL34 CLARIFY-PROGNOSTIC study is a nationwide platform that offers real-time, centralized risk assessment for patients with Large B Cell Lymphoma (LBCL) who are treated with frontline immunochemotherapy. This may help doctors make better treatment decisions, provide more accurate prognoses, and advance molecular and imaging techniques in Australia and New Zealand. The study also aims to identify ultra high-risk LBCL patients for clinical trials of new treatments, creating an efficient and cost-effective framework for future lymphoma trials. Who is it for? You may be eligible for this study if you are 18 or older and have been diagnosed with LBCL. Study Details LBCL patients will commence standard of care immunotherapy regimen. They will have a FDG/PET scan and/or a MRD assay at baseline, cycle 4, cycle 6, and 3 months after treatment ends. A positive disease will be based on centralized baseline tumor sequencing, centralized delta standardized uptake value (SUV) quantification / Deauville score, and measurable residual disease (MRD) testing. These patients will be referred to relevant therapeutic arms of this study, dependent on meeting relevant criteria. A UHR LBCL patient population will be identified and referred to a relevant therapuetic arm of this study to test novel treatments such as CAR-T cell infusion. This research aims to evaluate the feasibility of achieving faster turnaround rates for centralized MRD and FDG-PET reviews, to identify an UHR population to get them on appropriate treatment sooner. By meeting the following benchmarks in real time, the study will significantly contribute to the field by enhancing the speed and accuracy of prognostic processes: • MRD analysis and report turnaround must be completed within 21 days from sample collection. • FDG-PET scan reports must be ready within 7 days for SUV/Deauville score at C4D15, C6D15, and 3 months after the end of treatment.

The purpose of this study is to investigate the combination and efficacy and safety of Low dose Cytarabine, Venetoclax, Midostaurin and Pracinostat in patients with acute myeloid Leukaemia (AML). Who is it for? You may be eligible for this study if you are an adult over 60 years of age who has been diagnosed with AML, with no previous chemotherapy treatment. Study details Participants in this study will receive the following treatments: Depending on which Part of the trial is open for recruitment, patients eligible after screening will be registered to either 1. Part 1 - The dose finding Run-in phase 2. Part 1A - Run in phase or 3. Part 2 - The randomised phase 2 study The Run-Phase patients will receive either: LDAC (Low dose cytarabine) + venetoclax + midostaurin or LDAC (Low dose cytarabine) + venetoclax + pracinostat The part 1A run in phase patients will receive venetoclax + azacitidine + midostaurin The Randomised Phase patients will receive: 1. LDAC + venetoclax (Tablets) + midostaurin (Tablets) a. LDAC 20mg/m2 subcutaneously daily D1-10 of each cycle. b. Venetoclax (Tablets) RP2D (ramp up in cycle 1 only) c. Midostaurin (Tablets) RP2D or 2. LDAC + venetoclax + pracinostat a. LDAC 20mg/m2 subcutaneously daily D1-10 of each cycle. b. Venetoclax (Tablets)RP2D (ramp up in cycle 1 only) c. Pracinostat (Tablets) RP2D or 3. LDAC + venetoclax a. LDAC 20mg/m2 subcutaneously daily D1-10 of each cycle. b. Venetoclax 600mg (Tablets)D1-28 (ramp up in cycle 1 only) All participants will undertake blood tests, bone marrow biopsies and questionnaires. This study aims to establish whether the combination of treatments, can control the disease more effectively for a longer duration.

In order to prolong peritoneal dialysis [PD] technique survival, clinicians not only need to focus on protecting patient’s residual kidney function and peritoneal membrane integrity, they also need to address the impact of PD on patient’s daily living. One potential solution is the use of incremental PD (5 days a week dialysis). We have designed an investigator-initiated study to answer the following questions: Is incremental PD a feasible dialysis prescription? • Can PD patients be safely maintained on incremental PD • How long does incremental PD last, until needing daily PD By having regular peritoneal membrane resting, does incremental PD • Maintain residual renal function and urine output? • Improve patient’s life participation? • Better preserve peritoneal membrane function? The study will recruit adult patients who have commenced peritoneal dialysis in the previous 3 months and has been designed to fit in with PD patients' standard of care so minimal additional pathology testing will be required. We expect the incremental dialysis group to report better quality of life and demonstrate non-inferiority in terms of safety data and peritonitis rates.

The purpose of this study is to assess the feasibility of collecting data on cognition over the course of treatment and recovery in patients with newly diagnosed aggressive lymphoma Who is it for? You may be eligible for this study if you are an adult who has been newly diagnosed with aggressive lymphoma, that is undergoing treatment at Austin Health. Study details All participants in this study will complete their usual treatment as prescribed by their doctor. Participants in this study will be assessed at three timepoints over the course of their treatment and recovery – one before treatment starts, one halfway, and one at the end of the treatment period. The assessment session will involve some tests to assess cognitive function and, in those participants willing to participate, a MRI brain scan and/or a PET/CT brain scan. It is hoped that this research will help determine if a larger study looking at cognitive function during chemotherapy for lymphoma is possible, adding to an underexplored area of cancer research.

The aim of this study is to assess the feasibility of a future substantive randomised controlled trial comparing the efficacy of an internet delivered interventions for rotator cuff related pain delivered via three methods. The three trial arms are; (i) usual care basic advice (about rotator cuff related pain and activity modification); (ii) the combination of online printable pamphlet and video, plus a "virtual physiotherapist" whereby participants enter their exercise and symptoms into the website and it tailors their exercise (iii) the combination of online printable pamphlet, video and "virtual physiotherapist" plus a weekly telerehabilitation session with a physiotherapist (via Zoom®).

This study aims to evaluate the need for Intravenous Fentanyl to provide Procedural analgesia during Direct Current Cardioversion for the treatment of acute onset Atrial fibrillation. Patents will be randomised to receive a pain relief medication (Fentanyl) or a placebo (Salt water) at the commencement of the procedure. All other elements of the procedure are the same. when the patient emerges and can state their name, the clinician will ask the patient to rank their perception of pain. This will be repeated at 10 minutes from the time the patient was able to state their name. The two groups will be compared to see if the patients receiving the Fentanyl rated their pain differently , to those that did not receive pain relief. This study aims to redefine and change clinical practice, avoid use of treatments when they are not indicated, improve patient safety by reducing harm from unnecessary treatments or interventions.

Knee Osteoarthritis affects many people, causing significant pain and immobility. At present, there are very few effective treatments available to managing pain in patients with osteoarthritis. This study is designed to investigate a new treatment, called a 'Genicular nerve block'. This study aims to demonstrate that 'Genicular nerve block' is a safe and effective method for treating knee osteoarthritis.

The purpose of this study is to test the effect of Acceptance and Commitment Therapy on wellbeing. Who is it for? You may be eligible for this study if you are aged 18 or over, and have had treatment for breast cancer within the last 2 years. Study details Participants in this study will be randomised by chance (like flipping a coin) into two groups. One group (comparator) will continue treatment as usual, and will be able to access the intervention after a 3 month wait. The other group will immediately commence the intervention. The intervention, called Acceptance and Commitment Therapy involves six 90min group sessions, one session per week, with a psychologist. The intervention also involves some homework tasks between sessions. As part of the study, all participants will complete questionnaires. It is hoped that this study will contributed to improved quality of life in breast cancer survivors.